Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naïve, Transfusion-Dependent (TD), Lower-Risk Myelodysplastic Syndromes (LR-MDS): Results from the Phase 3 COMMANDS Study

Esther Natalie Oliva, Uwe Platzbecker, Matteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, Pierre Fenaux, Jake Shortt, Rami S. Komrokji, Christopher Pelligra, Shien Guo, Jennifer Lord-Bessen, Hong Xiao, Aylin Yucel, Dimana Miteva, Shelonitda Rose, Sandra Kreitz, Mikkael A. Sekeres, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 4596.

https://doi.org/10.1182/blood-2023-174660

Published: 2023

Journal Articles

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial

Michel Delforge, Krina K. Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S. Marshall, Bertrand Arnulf, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Sergio A. Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa-McKiver, Mark Cook, Paula Rodriguez Otero

Blood (2023) 142 (Supplement 1): 96.

https://doi.org/10.1182/blood-2023-179152

Published: 2023

Journal Articles

Patient-Reported Outcomes (PROs) from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL)

Guillaume Cartron, Alejandro Martin Garcia-Sancho, Juan Luis Reguera, Saurabh Dahiya, Shien Guo, Ling Shi, Laurie Eliason, Jinender Kumar, Thalia Farazi, Omotayo Fasan, Koji Izutsu

Blood (2023) 142 (Supplement 1): 668.

https://doi.org/10.1182/blood-2023-180175

Published: 2023

Journal Articles

Patient-Reported Outcomes from the MCL Cohort of the Phase 1, Seamless Design TRANSCEND NHL 001 Study of Lisocabtagene Maraleucel in Patients with R/R B-Cell NHL

Michael L. Wang, Leo I. Gordon, Alexandre V Hirayama, Matthew A Lunning, Ling Shi, Shien Guo, Ana Kostic, Laurie Eliason, Jinender Kumar, Maria Lia Palomba

Blood (2023) 142 (Supplement 1): 667.

https://doi.org/10.1182/blood-2023-180014

Published: 2023

Journal Articles

Durable Symptom Improvement for Patients with Non-Transfusion Dependent Thalassemia Treated with Luspatercept: Patient-Reported Outcomes from the BEYOND Study

Khaled M Musallam, Ali T Taher, Antonis Kattamis, Maria Domenica Cappellini, Jennifer Lord-Bessen, Mrudula Glassberg, Christopher Pelligra, Shien Guo, Loyse Felber Medlin, Luciana Moro Bueno, Kevin H.M. Kuo

Blood (2023) 142 (Supplement 1): 2474.

https://doi.org/10.1182/blood-2023-173366

Published: 2023

Journal Articles

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Triple-Class-Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Who Received at Least 3 Lines of Prior Antimyeloma Regimens in the KarMMa-3 Phase 3 Randomized Controlled Trial

Blood (2023) 142 (Supplement 1): 1003.

https://doi.org/10.1182/blood-2023-173849

Published: 2023

Journal Articles

Net Clinical and Quality of Life Benefit of Luspatercept in Transfusion-Dependent MDS: A Win Ratio Analysis Using Data from the Phase 3 MEDALIST Study

Esther Natalie Oliva, Christopher Pelligra, Jennifer Lord-Bessen, Shien Guo, Jan Sieluk, Mrudula B. Glassberg, Dimana Miteva, Aylin Yucel

Blood (2023) 142 (Supplement 1): 6467.

https://doi.org/10.1182/blood-2023-173368

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2 ) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)

Courtney D. DiNardo, Hartmut Dohner, Amer M. Zeidan, Andre C. Schuh, Paresh Vyas, Eytan M. Stein, Andrew H. Wei, Stephane de Botton, Clara Chen, Jennifer Lord-Bessen, Patricia Martin-Regueira, Frederik Lersch, Jing Gong, Shien Guo, Ling Shi, Pau Montesinos

Blood (2021) 138 (Supplement 1): 1244.

https://doi.org/10.1182/blood-2021-147601

Published: 2021

Journal Articles

Updated Health-Related Quality of Life Results from the KarMMa Clinical Study in Patients with Relapsed and Refractory Multiple Myeloma Treated with the B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Idecabtagene Vicleucel (ide-cel, bb2121)

Michel Delforge, Nina Shah, Paula Rodríguez-Otero, Julia Braverman, Devender Dhanda, Ling Shi, Shien Guo, Peiwen Yu, Weiqin Liao, Timothy B. Campbell, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 2835.

https://doi.org/10.1182/blood-2021-145155

Published: 2021

Journal Articles

Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma ( LBCL): Results from the Phase 3 Transform Study

Jeremy S. Abramson, Scott R. Solomon, Jon E. Arnason, Patrick B. Johnston, Bertram Glass, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Fei Fei Liu, Julia Braverman, Shien Guo, Ling Shi, Manali Kamdar

Blood (2021) 138 (Supplement 1): 3845.

https://doi.org/10.1182/blood-2021-151611

Published: 2021

Journal Articles

Luspatercept Improves Quality of Life and Reduces Red Blood Cell Transfusion Burden in Patients with Non-Transfusion-Dependent β-Thalassemia in the BEYOND Trial

Antonis Kattamis, Vip Viprakasit, Maria Domenica Cappellini, Ersi Voskaridou, Antonio Piga, John B. Porter, Thomas D. Coates, Gian Luca Forni, Jeevan K. Shetty, Dimana Miteva, Oriana Esposito, Wen-Ling Kuo, Shien Guo, Christopher Pelligra, Jennifer Lord-Bessen, Aylin Yucel, Ali T. Taher

Blood (2021) 138 (Supplement 1): 3081.

https://doi.org/10.1182/blood-2021-148535

Published: 2021

Journal Articles

Health-Related Quality of Life Outcomes for Patients with Transfusion-Dependent Beta-Thalassemia Treated with Luspatercept in the Believe Trial

Maria Domenica Cappellini, Ali T. Taher, Antonio Piga, MD, Farrukh Shah, Ersi Voskaridou, Vip Viprakasit, John B. Porter, MA, MD, FRCP, FRCPath, Olivier Hermine, Ellis J. Neufeld, Alexis A. Thompson, MD, Derek Tang, Peiwen Yu, Shien Guo, Jeevan K. Shetty, Dimana Miteva, Tatiana Zinger, Jay T. Backstrom, Esther Natalie Oliva, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-136312

Published: 2020

Journal Articles

Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the Medalist Study

Esther Natalie Oliva, MD, Uwe Platzbecker, Guillermo Garcia-Manero, MD, Ghulam J. Mufti, Professor, Valeria Santini, Mikkael A. Sekeres, Rami S. Komrokji, MD, Jeevan K. Shetty, Derek Tang, Shien Guo, Weiqin Liao, George Zhang, Xianwei Ha, Rodrigo Ito, Jennifer Lord-Bessen, Jay T. Backstrom, Pierre Fenaux, MD PhD

Blood (2020) 136 (Supplement 1): 10–12.

https://doi.org/10.1182/blood-2020-136276

Published: 2020

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study

Ruben A Mesa, MD, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Derek Tang, PhD BSPharm, Angela Hu, MS, EDM, Carrie Brownstein, MD, Shien Guo, PhD, Xiaomei Ye, MS, Claire N Harrison, Professor

Blood (2019) 134 (Supplement_1): 704.

https://doi.org/10.1182/blood-2019-129020

Published: 2019

Journal Articles

Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Eric Jourdan, MD, Richard T. Silver, MD, Harry C Schouten, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Derek Tang, PhD BSPharm, Angela Hu, MS, EDM, Shien Guo, PhD, Weiqin Liao, MS, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 2207.

https://doi.org/10.1182/blood-2019-129386

Published: 2019

Journal Articles

The Impact of Lenalidomide, Bortezomib, and Dexamethasone Treatment on Health-Related Quality of Life in Transplant-Eligible Patients with Newly-Diagnosed Multiple Myeloma: Results from the IFM/DFCI 2009 Trial

Murielle Roussel, Benjamin Hebraud, Cyrille Hulin, Aurore Perrot, Denis Caillot, Margaret Macro, Bertrand Arnulf, Karim Belhadj, Laurent Garderet, Thierry Facon, Shien Guo, Arman Altincatal, Sujith Dhanasiri, Xavier Leleu, MD PhD, Philippe Moreau, Michel Attal

Blood (2018) 132 (Supplement 1): 716.

https://doi.org/10.1182/blood-2018-99-111477

Published: 2018

Journal Articles

Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm Study

Blood (2018) 132 (Supplement 1): 1960.

https://doi.org/10.1182/blood-2018-99-112155

Published: 2018

Journal Articles

Matching-Adjusted Indirect Comparison of Relative Efficacies Is Feasible and Useful in the Multiple Myeloma Therapy Landscape: A Comparison of Pomalidomide Plus Low-Dose Dexamethasone Versus Daratumumab

Kejal Parikh, Irina Proskorovsky, MSc, Safiya Abouzaid, Stanimira Krotneva, MSc, Veronique Page, MSc, Christopher G Pelligra, BA, Shien Guo, PhD, Jorge L Mouro, Sikander Ailawadhi, MD

Blood (2016) 128 (22): 5946.

https://doi.org/10.1182/blood.V128.22.5946.5946

Published: 2016

Journal Articles

A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial

Thierry Facon, Cyrille Hulin, Meletios A. Dimopoulos, Andrew Belch, Nathalie Meuleman, Mohamad Mohty, Wen-Ming Chen, Kihyun Kim, Elena Zamagni, Paula Rodriguez-Otero, MD PhD, William Renwick, Christian Rose, Adrian Tempescul, Antonio Palumbo, Shien Guo, Michael Sturniolo, Annette Ervin-Haynes, Jean-Paul Fermand

Blood (2015) 126 (23): 4239.

https://doi.org/10.1182/blood.V126.23.4239.4239

Published: 2015

Journal Articles

Healthcare Resource Utilization Trends over Time with Continuous Lenalidomide Treatment (Tx) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM)

Katja Weisel, MD, Dan T. Vogl, Michel Delforge, MD PhF, Kevin Song, Meletios Dimopoulos, Jamie Cavenagh, Cyrille Hulin, Philippe Rodon, Bertrand Arnulf, Robin Foá, MD, Albert Oriol, MD, Shien Guo, Mara Silvia Monzini, Jason Van Oostendorp, Annette Ervin-Haynes, Thierry Facon, MD

Blood (2014) 124 (21): 1326.

https://doi.org/10.1182/blood.V124.21.1326.1326

Published: 2014

NARROW

Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naïve, Transfusion-Dependent (TD), Lower-Risk Myelodysplastic Syndromes (LR-MDS): Results from the Phase 3 COMMANDS Study

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial

Patient-Reported Outcomes (PROs) from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL)

Patient-Reported Outcomes from the MCL Cohort of the Phase 1, Seamless Design TRANSCEND NHL 001 Study of Lisocabtagene Maraleucel in Patients with R/R B-Cell NHL

Durable Symptom Improvement for Patients with Non-Transfusion Dependent Thalassemia Treated with Luspatercept: Patient-Reported Outcomes from the BEYOND Study

Net Clinical and Quality of Life Benefit of Luspatercept in Transfusion-Dependent MDS: A Win Ratio Analysis Using Data from the Phase 3 MEDALIST Study

Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2 ) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)

Updated Health-Related Quality of Life Results from the KarMMa Clinical Study in Patients with Relapsed and Refractory Multiple Myeloma Treated with the B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Idecabtagene Vicleucel (ide-cel, bb2121)

Luspatercept Improves Quality of Life and Reduces Red Blood Cell Transfusion Burden in Patients with Non-Transfusion-Dependent β-Thalassemia in the BEYOND Trial

Health-Related Quality of Life Outcomes for Patients with Transfusion-Dependent Beta-Thalassemia Treated with Luspatercept in the Believe Trial

Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the Medalist Study

Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study

Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

The Impact of Lenalidomide, Bortezomib, and Dexamethasone Treatment on Health-Related Quality of Life in Transplant-Eligible Patients with Newly-Diagnosed Multiple Myeloma: Results from the IFM/DFCI 2009 Trial

Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm Study

Matching-Adjusted Indirect Comparison of Relative Efficacies Is Feasible and Useful in the Multiple Myeloma Therapy Landscape: A Comparison of Pomalidomide Plus Low-Dose Dexamethasone Versus Daratumumab

A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial

Healthcare Resource Utilization Trends over Time with Continuous Lenalidomide Treatment (Tx) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only